Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DD1TJ8
|
|||
| Drug Name |
XmAb20717
|
|||
| Synonyms |
XmAb717
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Advanced malignancy [ICD-11: 2A00-2F9Z] | Phase 1 | [1] | |
| Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 1 | [2] | ||
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1 | [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [1] | ||
| Company |
Xencor
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cytotoxic T-lymphocyte protein 4 (CTLA-4) | Target Info | . | [3] |
| Programmed cell death protein 1 (PD-1) | Target Info | . | [3] | |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Autoimmune thyroid disease | ||||
| Rheumatoid arthritis | ||||
| Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| Reactome | CTLA4 inhibitory signaling | |||
| PD-1 signaling | ||||
| WikiPathways | Vitamin D Receptor Pathway | |||
| T-Cell Receptor and Co-stimulatory Signaling | ||||
| Allograft Rejection | ||||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. | |||
| REF 2 | ClinicalTrials.gov (NCT03517488) A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2). U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of Xencor. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.